Synvista Therapeutics, Inc

Quick facts

Phase 2 pipeline

• BXT-51072 · Diabetes
  BXT-51072 is a small molecule inhibitor of the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Synvista Therapeutics, Inc portfolio CI brief
• Synvista Therapeutics, Inc pipeline updates RSS